亚宝药业集团股份有限公司 信息披露制度 第一章 总则 第一条 为规范亚宝药业集团股份有限公司（以下简称"公司"）信息披露行为， 加强信息披露事务管理，维护公司和投资者的合法权益，根据《中华人民共和国公司 法》（以下简称"《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《上 市公司信息披露管理办法》《上海证券交易所股票上市规则》（以下简称"《股票上市 规则》"）以及《亚宝药业集团股份有限公司章程》（以下简称"公司章程"）的有关规 定，并结合公司的实际情况，制定本制度。 第二条 本制度所称"信息"是指所有可能对公司股票及其衍生品种交易价格产生 重大影响的信息，以及证券监督管理部门和上海证券交易所要求或公司主动披露的信 息；本制度所称"披露"是指在规定的时间内，在中国证券监督管理委员会（以下简 称"中国证监会"）指定的媒体上，以规定的方式向社会公众公布前述信息，并按规 定报送证券监管部门和上海证券交易所。 第三条 公司的信息披露义务人包括但不限于： （一）公司及全体董事、高级管理人员； （二）公司股东、实际控制人； （三）收购人及其他权益变动主体，重大资产重组、再融资、重大交易有关各方 等自然人、单 ...

亚宝药业集团股份有限公司 董事和高级管理人员所持本公司股份及其变动管理制度 第一章 总则 第一条 为加强对亚宝药业集团股份有限公司（以下简称"公司"）董事和 高级管理人员所持本公司股份及其变动的管理，根据《中华人民共和国公司法》 （以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券 法》"）、《上市公司董事和高级管理人员所持本公司股份及其变动管理规则》 《上市公司股东减持股份管理暂行办法》《上海证券交易所股票上市规则》（以 下简称"《股票上市规则》"）《上海证券交易所上市公司自律监管指引第8 号——股份变动管理》《上海证券交易所上市公司自律监管指引第15号——股东 及董事、高级管理人员减持股份》等法律、行政法规、部门规章、规范性文件 （以下统称"法律法规"），以及《亚宝药业集团股份有限公司章程》（以下简 称"公司章程"）的有关规定，制定本制度。 公司董事、高级管理人员等主体对持有股份比例、持有期限、变动方式、 变动数量、变动价格等作出承诺的，应当严格履行所作出的承诺。 第三条 公司董事和高级管理人员所持本公司股份，是指登记在其名下和利 用他人账户持有的所有本公司股份。 公司董事和高级管理人员 ...

证券代码：600351 证券简称：亚宝药业 公告编号：2025-039 亚宝药业集团股份有限公司 第九届董事会第十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 亚宝药业集团股份有限公司（以下简称"公司"）第九届董事会第十次会议通 知于 2025 年 10 月 14 日以电子邮件和电话的方式发出，会议于 2025 年 10 月 24 日在公司北京企管中心会议室召开,会议应到董事 9 人，实到董事 9 人，符合《公 司法》及《公司章程》的有关规定。公司高级管理人员列席了会议。会议由公司 董事长任武贤先生主持，会议审议并经表决通过了如下决议： 一、审议通过了公司 2025 年第三季度报告； 同意 9 票，反对 0 票，弃权 0 票。 具体内容详见上海证券交易所网站（www.sse.com.cn）。 三、审议通过了关于制定《亚宝药业集团股份有限公司董事和高级管理人员 所持本公司股份及其变动管理制度》的议案； 同意 9 票，反对 0 票，弃权 0 票。 具体内容详见上海证券交易所网站（www.sse.com.cn）。 ...

Core Viewpoint - The financial performance of Yabao Pharmaceutical (600351) has declined significantly in Q3 2025, primarily due to the termination of the SY009 research project and the provision for asset impairment [1] Financial Performance Summary - Q3 2025 revenue reached 569 million yuan, a year-on-year decrease of 16.01% [1] - Q3 2025 net profit was 40.6971 million yuan, down 26.22% year-on-year [1] - Revenue for the first three quarters totaled 1.709 billion yuan, reflecting a 19.46% year-on-year decline [1] - Net profit for the first three quarters was 215 million yuan, a decrease of 8.44% year-on-year [1] - Basic earnings per share stood at 0.3066 yuan [1]

Financial Performance - The company's operating revenue for Q3 2025 was ¥569,303,758.32, a decrease of 16.01% compared to the same period last year[2] - Total profit for the quarter was ¥40,933,824.50, down 42.51% year-on-year[2] - Net profit attributable to shareholders was ¥40,697,053.18, reflecting a decline of 26.22% compared to the previous year[2] - The company reported a decrease of 30.84% in net profit after deducting non-recurring gains and losses due to the termination of the SY009 R&D project[7] - The basic earnings per share for the quarter was ¥0.0583, down 24.23% year-on-year[2] - Total revenue for the first three quarters of 2025 was CNY 1,708,712,223.13, a decrease of 19.4% compared to CNY 2,121,509,818.79 in the same period of 2024[16] - Net profit for the first three quarters of 2025 was CNY 198,491,469.17, down 13.1% from CNY 228,467,854.51 in the same period of 2024[18] - Earnings per share for the first three quarters of 2025 was CNY 0.3066, compared to CNY 0.3241 in 2024, reflecting a decrease of 5.5%[18] Cash Flow and Assets - The net cash flow from operating activities increased significantly by 221.16% to ¥129,363,179.19[2] - Cash and cash equivalents increased to ¥645,407,882.65 from ¥578,594,453.98, reflecting a growth of approximately 11.43%[13] - Total current assets decreased to ¥1,484,605,647.29 from ¥1,559,311,767.72, a decline of about 4.79%[13] - Cash inflow from sales of goods and services was $1.64 billion, compared to $1.84 billion in the previous period, reflecting a decrease of 11.1%[21] - Total cash outflow from operating activities was $1.30 billion, down from $1.52 billion in the previous period, indicating a reduction of 14.4%[21] - Cash received from investment recoveries was $144.77 million, a significant increase from $4.87 million in the previous period[22] - Cash paid for fixed assets and intangible assets was $38.77 million, compared to $28.32 million in the previous period, representing an increase of 36.8%[22] Shareholder Information - Total shareholders at the end of the reporting period reached 53,669[9] - The largest shareholder, Shanxi Yabao Investment Group Co., Ltd., holds 94,300,000 shares, accounting for 13.47% of total shares[9] - The top ten shareholders do not have any related party relationships or concerted actions among them[11] - The company has not reported any significant changes in the participation of major shareholders in securities lending or borrowing activities[11] Assets and Liabilities - The total assets at the end of the reporting period were ¥3,342,721,351.58, a decrease of 5.68% from the end of the previous year[3] - The equity attributable to shareholders decreased by 3.35% to ¥2,795,760,982.69[3] - Total liabilities decreased to CNY 585,773,356.92 from CNY 649,023,044.55, a reduction of 9.8%[15] - Non-current assets totaled CNY 1,858,115,704.29, down from CNY 1,984,630,806.62, indicating a decrease of 6.4%[15] Operating Costs and Expenses - Total operating costs for the first three quarters of 2025 were CNY 1,422,105,604.68, down from CNY 1,854,942,934.53 in 2024, reflecting a reduction of 23.3%[16] - Operating profit for the first three quarters of 2025 was CNY 253,258,850.67, compared to CNY 288,373,771.98 in 2024, indicating a decline of 12.2%[17] - The company reported a significant reduction in sales expenses, which were CNY 327,463,027.22 in 2025 compared to CNY 514,819,616.99 in 2024, a decrease of 36.3%[17] - Research and development expenses for the first three quarters of 2025 were CNY 72,291,467.66, down from CNY 89,911,769.62 in 2024, reflecting a decrease of 19.7%[17]

格隆汇10月24日丨亚宝药业(600351.SH)公布三季度报告，前三季营业收入17亿元，同比下降19.46%， 归属于上市公司股东的净利润2.15亿元，同比下降8.44%，归属于上市公司股东的扣除非经常性损益的 净利润1.97亿元，同比下降9.03%。 ...

Core Insights - The company reported a third-quarter revenue of 569 million yuan, representing a year-on-year decline of 16.01% [1] - The net profit for the third quarter was 40.7 million yuan, down 26.22% year-on-year [1] - For the first three quarters, the total revenue was 1.709 billion yuan, reflecting a year-on-year decrease of 19.46% [1] - The net profit for the first three quarters amounted to 215 million yuan, which is an 8.44% decline compared to the previous year [1]

| 交易日期 | | 证券代码 | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | | 卖出营业部 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-10-23 | 亚宝药业 | 600351 | 6.83 273.2 | 40 | 机构专用 | 去夢髮發驚拿舞蹈 | Ka | 10月23日，亚宝药业大宗交易成交40万股，成交额273.2万元，占当日总成交额的3.19%，成交价6.83 元，较市场收盘价6.83元持平。 ...

Core Points - The company announced that its wholly-owned subsidiary, Beijing Yabao Biological Pharmaceutical Co., Ltd., has received the drug registration certificate for Sitagliptin Metformin Extended-Release Tablets from the National Medical Products Administration [1] Group 1 - The drug registration certificate has the number 2025S03027 [1]

Group 1 - Harbin Air Conditioning plans to transfer 40% equity of its subsidiary, Harbin Fushanchuan Biotechnology Development Co., Ltd. The subsidiary reported a net profit of -16.0963 million yuan for 2024, which is 218.83% of the previous year's net profit absolute value [1] - Xinhua Insurance expects a net profit of 29.986 billion to 34.122 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 45% to 65% [1][2] - Gansu Energy anticipates a net profit of 1.55 billion to 1.6 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 11.86% to 15.47% [2][3] Group 2 - Dongfang Tower forecasts a net profit of 750 million to 900 million yuan for the first three quarters of 2025, indicating a year-on-year growth of 60.83% to 93% [4] - Meili Eco announced that its subsidiary won a bid for an EPC project worth 2.375 billion yuan [6] - Bohai Chemical's wholly-owned subsidiary will undergo routine maintenance for its 600,000 tons/year PDH unit, expected to last about 30 days [8] Group 3 - Qin Port Co. reported a total throughput of 317.02 million tons for the first nine months of 2025, a year-on-year increase of 5.56% [10] - Jianglong Shipbuilding won a bid for a 72.99 million yuan fishery enforcement vessel project, accounting for 4.22% of its 2024 audited revenue [11] - Longyuan Technology expects a net profit of 35 million to 40 million yuan for the first three quarters of 2025, representing a year-on-year increase of 50.11% to 71.55% [12] Group 4 - Naipu Mining anticipates a net profit of 61 million to 66 million yuan for the first three quarters of 2025, reflecting a year-on-year decline of 45.16% to 49.32% [14] - Jinggong Steel Structure reported a cumulative contract amount of 17.98 billion yuan for the first nine months of 2025, a year-on-year increase of 4.8% [15][16] - Shenzhen Gas reported a net profit of 918 million yuan for the first three quarters of 2025, a year-on-year decrease of 13.08% [17] Group 5 - Yabao Pharmaceutical's subsidiary received a drug registration certificate for a new diabetes medication [18] - Shaanxi Coal's coal production in September was 14.56 million tons, a year-on-year increase of 5.34% [20] - Sifang New Materials reported a 15.94% year-on-year decline in concrete production for the first three quarters [22] Group 6 - Nanjing Foods reported a consolidated revenue of 276 million yuan in September, a slight increase of 0.0016% year-on-year [23] - Pulaike received a new veterinary drug registration certificate for a flea and tick treatment [24] - Zhucheng Technology received a cash dividend of 15 million yuan from its subsidiary [25] Group 7 - David Medical's subsidiary received a medical device registration certificate for a portable electronic endoscope image processor [26] - Zhongtong Bus reported a 36.88% year-on-year increase in sales in September, totaling 1,106 units [27] - Xiantan Co. reported a 11.95% year-on-year increase in chicken sales revenue in September [28] Group 8 - Bojun Technology expects a net profit of 552 million to 662 million yuan for the first three quarters of 2025, a year-on-year increase of 50% to 80% [30] - Haishi Pharmaceutical's innovative pain relief drug clinical trial application has been accepted [31] - Lingxiao Pump Industry used 80 million yuan of idle funds to purchase financial products [32] Group 9 - Qiangda Circuit's subsidiary completed business registration changes to expand its operational scope [33] - *ST Tianyu's controlling shareholder applied for bankruptcy liquidation due to severe financial difficulties [34] - Baolidi's shareholder plans to reduce holdings by up to 1 million shares [36] Group 10 - Zijin Mining completed the acquisition of Kazakhstan's Raygorodok gold mine, controlling 100% of its rights [44] - Zhonggang Luoyang's indirect controlling shareholder completed a capital increase, raising registered capital from approximately 26.666 billion yuan to 44.824 billion yuan [46] - Jinyu Jidong's director resigned due to work adjustments [47]